The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases

摘要: Depletion of regulatory T (TReg) cells in otherwise healthy individuals leads to multi-organ autoimmune disease and inflammation. This indicates that a normal immune system, there are self-specific effector ready attack tissue if they not restrained by TReg cells. The data imply is balance between health suggest therapeutic potential diseases which this altered. Proof-of-concept clinical trials, now supported robust mechanistic studies, have shown low-dose interleukin-2 specifically expands activates cell populations thus can control